| Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. (NCT07595276) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2026-06-01 |
| Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers (NCT07254325) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2025-12-15 |
| Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers (NCT07246291) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2025-11-11 |
| Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors (NCT06933069) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2025-06-09 |
| Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (NCT06398652) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2024-08-27 |
| To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria (NCT06365879) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2024-06-18 |
| Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects (NCT07246252) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2024-03-28 |
| Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers (NCT06361355) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-11-02 |
| Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients (NCT05906576) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-09-21 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers (NCT05734482) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-02-15 |
| Study of CMAB807X Pre- and Post-change in Manufacturing Site and Xgeva® in Healthy Volunteers (NCT05808673) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2023-02-01 |
| The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity (NCT05897008) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2022-02-07 |
| The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety (NCT04778137) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2020-12-01 |
| Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (NCT04659369) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2020-09-24 |
| The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety (NCT04779892) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2020-02-01 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB809 and Herceptin in Healthy Volunteers (NCT04049409) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2019-06-17 |
| CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (NCT03206151) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2017-12-12 |